Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408653/ https://www.ncbi.nlm.nih.gov/pubmed/37560255 http://dx.doi.org/10.2147/CCID.S407813 |
_version_ | 1785086210788556800 |
---|---|
author | Potestio, Luca Camela, Elisa Cacciapuoti, Sara Fornaro, Luigi Ruggiero, Angelo Martora, Fabrizio Battista, Teresa Megna, Matteo |
author_facet | Potestio, Luca Camela, Elisa Cacciapuoti, Sara Fornaro, Luigi Ruggiero, Angelo Martora, Fabrizio Battista, Teresa Megna, Matteo |
author_sort | Potestio, Luca |
collection | PubMed |
description | Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fatigue, dehydration, serum electrolyte disturbances, and tachycardia making this condition a possible life-threatening disease, particularly if appropriate treatments are not performed. In this scenario, effective and safe therapies are required. Unfortunately, the rarity of EP makes head-to-head Phase III trials challenging, leading to the lack of established guidelines for its management. Globally, conventional systemic drugs such as cyclosporine, methotrexate, and retinoids often have contraindications linked to patients’ comorbidities and have not shown a high profile of efficacy and safety. Recently, the development of biologic drugs including anti-tumor necrosis factor-α and anti-interleukin 12–23, 23, and 17 has revealed favorable results for the management of plaque psoriasis, making them also a possible therapeutic option for EP disease. However, their use in EP is still off-label. The aim of our study was to review current literature on the use of biologic drugs for the treatment of EPs in order to offer a wide perspective on their possible application in EP management. |
format | Online Article Text |
id | pubmed-10408653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104086532023-08-09 Biologics for the Management of Erythrodermic Psoriasis: An Updated Review Potestio, Luca Camela, Elisa Cacciapuoti, Sara Fornaro, Luigi Ruggiero, Angelo Martora, Fabrizio Battista, Teresa Megna, Matteo Clin Cosmet Investig Dermatol Review Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fatigue, dehydration, serum electrolyte disturbances, and tachycardia making this condition a possible life-threatening disease, particularly if appropriate treatments are not performed. In this scenario, effective and safe therapies are required. Unfortunately, the rarity of EP makes head-to-head Phase III trials challenging, leading to the lack of established guidelines for its management. Globally, conventional systemic drugs such as cyclosporine, methotrexate, and retinoids often have contraindications linked to patients’ comorbidities and have not shown a high profile of efficacy and safety. Recently, the development of biologic drugs including anti-tumor necrosis factor-α and anti-interleukin 12–23, 23, and 17 has revealed favorable results for the management of plaque psoriasis, making them also a possible therapeutic option for EP disease. However, their use in EP is still off-label. The aim of our study was to review current literature on the use of biologic drugs for the treatment of EPs in order to offer a wide perspective on their possible application in EP management. Dove 2023-08-04 /pmc/articles/PMC10408653/ /pubmed/37560255 http://dx.doi.org/10.2147/CCID.S407813 Text en © 2023 Potestio et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Potestio, Luca Camela, Elisa Cacciapuoti, Sara Fornaro, Luigi Ruggiero, Angelo Martora, Fabrizio Battista, Teresa Megna, Matteo Biologics for the Management of Erythrodermic Psoriasis: An Updated Review |
title | Biologics for the Management of Erythrodermic Psoriasis: An Updated Review |
title_full | Biologics for the Management of Erythrodermic Psoriasis: An Updated Review |
title_fullStr | Biologics for the Management of Erythrodermic Psoriasis: An Updated Review |
title_full_unstemmed | Biologics for the Management of Erythrodermic Psoriasis: An Updated Review |
title_short | Biologics for the Management of Erythrodermic Psoriasis: An Updated Review |
title_sort | biologics for the management of erythrodermic psoriasis: an updated review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408653/ https://www.ncbi.nlm.nih.gov/pubmed/37560255 http://dx.doi.org/10.2147/CCID.S407813 |
work_keys_str_mv | AT potestioluca biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview AT camelaelisa biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview AT cacciapuotisara biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview AT fornaroluigi biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview AT ruggieroangelo biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview AT martorafabrizio biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview AT battistateresa biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview AT megnamatteo biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview |